Allarity Therapeutics Inc
NASDAQ:ALLR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Allarity Therapeutics Inc
NASDAQ:ALLR
|
13.1m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Allarity Therapeutics Inc
Glance View
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-12-21. The firm is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The company uses its DRP companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by its DRP companion diagnostics platform. Its lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptor (VEGFR). Its second priority therapeutic candidate, stenoparib, is a selective inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). Its third priority therapeutic candidate is IXEMPRA (ixabepilone).
